Table 2.
Association of SNPs with erythema for all patients as well as for the subgroups of patients with breast volume < or >750 cm³
| |
|
|
all patients |
|
patients with breast volume <750 cm³ |
|
patients with breast volume ≥750 cm³ |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 83) | (n = 48) | (n = 35) | ||||||||||||||||||||
| Gene (codon) |
Genotype |
aa |
n (%) |
G0/1a |
G2/3a |
ORb |
95% CIc |
Pd |
aa |
n (%) |
G0/1a |
G2/3a |
ORb |
95% CIc |
Pd |
aa |
n (%) |
G0/1a |
G2/3a |
ORb |
95% CIc |
Pd |
| ATM |
GG |
|
63 (76) |
28 |
35 |
1 |
|
|
|
36 (75) |
20 |
16 |
1 |
|
|
|
27 (77) |
8 |
19 |
1 |
0.19 – 5.68 |
|
| (1853) |
GA |
|
18 (22) |
9 |
9 |
1.18 |
0.45 – 3.25 |
0.826 |
|
11 (23) |
6 |
5 |
1.43 |
0.38 – 5.67 |
0.573 |
|
7 (20) |
3 |
4 |
0.92 |
0.04 – 32.21 |
1.000 |
| |
AA |
|
2 (2) |
0 |
2 |
1.38 |
0.20 – 10.59 |
|
|
1 (2) |
0 |
1 |
2.05 |
0.15 – 32.15 |
|
|
1 (3) |
0 |
1 |
0.84 |
|
|
| GSTP1 |
AA |
|
37 (45) |
19 |
18 |
1 |
|
|
|
21 (44) |
12 |
9 |
1 |
|
|
|
16 (46) |
7 |
9 |
1 |
|
|
| (105) |
AG |
|
38 (45) |
12 |
26 |
1.01 |
0.49 – 2.09 |
1.000 |
|
21 (44) |
10 |
11 |
0.98 |
0.39 – 2.44 |
1.000 |
|
17 (48) |
2 |
15 |
1.25 |
0.32 – 5.29 |
0.772 |
| |
GG |
|
8 (10) |
6 |
2 |
1.02 |
0.24 – 4.35 |
|
|
6 (12) |
4 |
2 |
0.96 |
0.15 – 5.97 |
|
|
2 (6) |
2 |
0 |
1.56 |
0.10 – 28.03 |
|
| TGFB1 |
CC |
|
29 (35) |
14 |
15 |
1 |
|
|
|
18 (38) |
13 |
5 |
1 |
|
|
|
11 (31) |
1 |
10 |
1 |
|
|
| (pos-509) |
CT |
|
40 (48) |
18 |
22 |
1.26 |
0.65 – 2.50 |
0.530 |
|
24 (50) |
12 |
12 |
3.10 |
1.11 –10.21 |
0.028 |
|
16 (46) |
6 |
10 |
0.36 |
0.10 – 1.14 |
0.083 |
| |
TT |
|
14 (17) |
5 |
9 |
1.59 |
0.42 – 6.24 |
|
|
6 (12) |
1 |
5 |
9.58 |
1.23 – 104.30 |
|
|
8 (23) |
4 |
4 |
0.13 |
0.01 – 1.29 |
|
| XPD e |
GG |
|
34 (42) |
19 |
15 |
1 |
|
|
|
20 (43) |
12 |
8 |
1 |
|
|
|
14 (40) |
7 |
7 |
1 |
|
|
| (751) |
GT |
|
38 (46) |
14 |
24 |
1.85 |
0.90 – 4.00 |
0.098 |
|
20 (43) |
10 |
10 |
1.42 |
0.59 – 3.59 |
0.420 |
|
18 (51) |
4 |
14 |
3.95 |
0.91 – 22.75 |
0.046 |
| |
TT |
|
10 (12) |
3 |
7 |
3.44 |
0.81 – 16.01 |
|
|
7 (14) |
3 |
4 |
2.03 |
0.34 – 12.89 |
|
|
3 (9) |
0 |
3 |
15.62 |
0.84 – 517.40 |
|
| XRCC1 |
GG |
|
36 (43) |
17 |
19 |
1 |
|
|
|
25 (52) |
14 |
11 |
1 |
|
|
|
11 (31) |
3 |
8 |
1 |
|
|
| (399) |
GA |
|
33 (40) |
13 |
20 |
1.02 |
0.54 – 1.93 |
1.000 |
|
17 (35) |
9 |
8 |
1.13 |
0.46 – 2.76 |
0.840 |
|
16 (46) |
4 |
12 |
0.62 |
0.20 – 1.84 |
0.464 |
| AA | 14 (17) | 7 | 7 | 1.04 | 0.29 – 3.73 | 6 (12) | 3 | 3 | 1.27 | 0.21 – 7.63 | 8 (23) | 4 | 4 | 0.39 | 0.04 – 3.39 | |||||||
a Patients with erythema of grade 0 or 1 and grade 2 or 3.
b Odds ratio per allele.
c 95% confidence interval.
d Two-sided p-value from the Cochran-Armitage trend test.
e Failure to genotype one patient.